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Abstract
Migraine is a very common type of headache. With
a prevalence of 10-12%, migraine ranks 19th among
diseases causing worldwide morbidity. Number of studies
have shown a high prevalence of patent foramen ovale
(PFO) in patients with migraine, especially migraine with
aura. The right to left shunting of blood in a PFO could
serve as a conduit for chemicals that would exert a trigger
effect on hyper excitable neurons leading to the
development of migraine. Furthermore patients with PFO
and migraine also show a marked improvement in their
symptoms after percutaneous closure of the PFO. This
review is a close look at this association and also explores
whether subsequent closure of the shunt can be looked upon
as a viable treatment option. 
Migraine
Migraine is a complex disorder in which many
psychological, environmental, biochemical, neurophysiologic,
and genetic factors play a role to trigger attacks. The diagnosis
is based on headache characteristics and associated symptoms
specified by the International Headache Society.1 The typical
headache is unilateral, throbbing, and may be severe. If
untreated, the migraine attacks typically last 4 to 72 hours. The
attacks are usually associated with nausea, vomiting, or
sensitivity to sound, light, or movement. In addition to this,
migraine with aura is characterized by transient focal
neurological symptoms, which are usually visual, and may
precede, accompany, or follow the headache attack.2
With a prevalence of 10-12%, migraine ranks 19th
among diseases causing worldwide morbidity.1 Its
prevalence increases with age until a peak prevalence of
approximately 27% in women and 8% in men is reached in
the fourth decade of life. Thereafter, it decreases with
increasing age.3
Patent Foramen Ovale (PFO)
Foramen ovale is a slit like opening in the atrial
septum. In the intrauterine life, foramen ovale has the
important role of transmitting highly oxygenated inferior
vena caval blood to the left atrium (LA). High right atrial
(RA) pressure in foetal life keeps the valve of foramen ovale
open. LA pressure rises shortly after birth and the flap is
lightly pushed against the septum secundum and closes the
foramen ovale functionally. Anatomic patency may occur
for several months and 50% of all the infants have probe -
PFO at the end of 1st year of life. However in a large
proportion, anatomic closure never occurs.
A number of studies have indicated PFO to be
present in around 25% to 30% of adult population, with
equal incidence in the sexes.4 It can allow only right-to-left
shunt (RLS) because of the flap which covers it from the left
side. TEE (Trans-esophageal echo) is better than Trans-
thoracic echo in diagnosing PFO.5
The right-to-left shunt (RLS) may be associated with
paradoxical embolization of thrombi and has been
postulated as a mechanism for cryptogenic stroke in young
adults.6 PFO has also been shown to cause decompression
sickness among divers.7
Migraine and PFO: Is it the shunt behind the
headache?
Migraine has long been suspected as a risk factor for
stroke. Several studies have linked migraine headache to
stroke, particularly in young women.8 However, discoveries
that the prevalence of PFO is the same in patients with
migraine with aura as in patients with cryptogenic stroke9-11
and that the frequency of migraine in PFO associated
cryptogenic stroke is twice what would otherwise be
expected12,13 lead to the speculation that PFO could play a
role in the pathogenesis of migraine headaches.
Theoretically, the presence of a right-to-left shunt in
a PFO could serve as a conduit for chemicals, that would be
normally inactivated by the pulmonary filter, to reach the
systemic circulation and exert a trigger effect on hyper
excitable neurons leading to development of migraines.
These substances may include vasoactive agents such as
atrial natriuretic peptide, platelet factors, and amines, which
in elevated concentrations can cause a migraine in
susceptible individuals even without a PFO.14
Although a theoretically plausible association, PFO
and migraine are common conditions and their co-
occurrence in a single patient might yet be coincidental;
alternately, PFO and migraine both could derive from a
common underlying disorder (e.g., a dysfunction in the
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endothelium) without necessarily being linked in a causal
relationship.15
However a number of studies have supported this
relationship and have validated the PFO-migraine association.
While Del Sette et al9 showed a statistically significant
association between the prevalence of PFO among
migraineurs versus controls; Anzola et al10 found that the
association varied with migraine subtype, as only patients with
aura had a higher occurrence of PFO when compared with
controls. Similar findings were reported by Schwerzmann et
al16 using trans-esophageal echocardiography, who found
PFO with large shunts more often in patients with migraine
with aura compared to control subjects.
Moreover, in patients with RLS, the prevalence of
migraine seems to be higher when compared to those
without a shunt. This finding was first reported by
Wilmshurst and Nightengale17 and later, similar findings
were reported by Sztajzel et al.13
Finally, the strength of the relationship between the
migraine and RLS due to PFO was assessed by Wammes-
van der Heijden et al18, who systematically reviewed
published relevant literature, and concluded that among
patients with RLS, migraine with aura was 3.5 times more
prevalent than among subjects without RLS (Mantel-
Haenszel odds ratio (ORMH) 3.5; 95% confidence interval
(CI) 2.1, 5.8). This further elicits a clear association
between RLS and migraine, especially migraine with aura.
Closing the Shunt: A possible treatment?
If PFO is the etiology behind migraine, can shunt
closure be a definitive treatment? When Wilmshurst et al
observed PFO closure to prevent decompression sickness in
a cohort of scuba divers, results showed a dramatic decrease
in migraine severity7; this finding raised considerable
interest on the possible curative effect of shunt closure on
migraine. A number of subsequent publications reported a
consistent benefit on migraine following PFO closure in
patients who had suffered a stroke.14,19-23 However, none of
these studies had a control group. Recently Kimmelstiel et
al24 in a controlled study showed PFO closure decrease the
frequency of migraine by 83% compared to 0% decrease in
frequency in open PFO and 10% decrease in the control
group (no PFO). Furthermore, preliminary results of
another recent case-control study have shown PFO closure
to be far more effective in reducing frequency, duration and
intensity of migraine attacks when compared to medical
treatment.25
There is evidence of a strong association between the
presence of a RLS and the occurrence of migraine. In
addition we have also seen that shunt closure is related to a
decrease in the prevalence of migraine, especially in
migraine with aura. Yet at this moment shunt closure cannot
be seen as a new treatment for PFO related migraines.
Most of the studies favouring PFO closure were
nonrandomized, lacked a control group and investigated a
relatively small number of patients with migraine. Before
percutaneous shunt closure can become a new treatment in
patients with migraine, especially migraine with aura, large
prospective randomized trials will be necessary. Finally, it is
worth recalling that, even if percutaneous closure of PFO is
a safe, effective, and minimally invasive procedure, a
number of complications have been reported. Among these,
special emphasis should be placed on major arrhythmias,
including supraventricular paroxysmal tachycardia and
atrial fibrillation, which have been documented in up to 8%
of patients within 1 month of the procedure.26,27
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Short Communication
Deliberate self-poisoning: Experience at a Medical Unit
Muhammad Khurram, Najia Mahmood. 
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Abstract
To share our experience of managing acute DSP
patients, a cross sectional, observational study was
conducted for one year. Patients with acute DSP, defined as
"ingestion of a poison or excessive dose of a medicine for
self-harm" were included. Patient demographics (gender,
age, educational, and marital status etc), intention,
substance used, and outcome were noted. Eighty patients
(47 female, and 33 male) were managed. Mean patient age
was 24.35±7.69 years. Most of the patients were educated
up to 10th grade, were unmarried, resident of urban area,
occupation wise household related, and belonged to middle
class. Majority (55%) of patients wanted to commit suicide.
Benzodiazepines (31.3%) and organophosphate (OP)
compounds (21.3%) were commonly used for DSP. 2.5%
(n=2) patients expired. DSP with OP compounds was
significantly associated with suicidal intention. 
Introduction 
Self-harming behavior has been noticed since
ancient times.1 Its nature and causes vary with various
religious, socioeconomic, ethnic, and cultural factors.
Deliberate self-harm syndrome (DSH) is the term used to
categorize this kind of behaviour. In it, persons with
apparent consciousness and willful intent perform painful,
destructive, and injurious acts upon their own bodies.2 In
terms of intent, persons who commit deliberate self-harm
can be divided into those who die, and those who harm
themselves.3 Deliberate self-poisoning (DSP) and self-
injury are main types of DSH.
DSP is an important health problem throughout the
world especially in developing countries.4 It is a major
cause of more than 500000 deaths per year attributed to
DSH in Asia Pacific region.3 DSP is commonest mode of
DSH in Pakistan.5,6 It is an important health issue in context
to adolescents and younger Pakistani population.5,6
Reported incidence of DSP in Pakistan is about 8 per
100,000 in men and women.5 This estimate has limitations
because of the fact that DSP evaluation in Pakistani settings
is difficult. It is a criminal offence as Islam prohibits suicide
in any form. Management of DSP patients at public
hospitals includes involvement of Police, from whom every
body in this country want to stay away. Patients and
attendants may thus ascribe DSP to accidental poisoning.1
DSP is thus underreported. 
Young, married females constitute majority of
persons attempting DSP.5,6 Commonest compound used for
DSP vary at different places. In developing countries like
Pakistan, benzodiazepines and OP pesticides are used
commonly in urban and rural areas respectively.4-6
Persons attempting DSP may have various intentions
of which manipulative/threatening, and suicidal are most
important.1 Majority of the persons attempting DSP don't
want to commit suicide.7 They do so as they are depressed,
have anger, jealousy, or desire for attention.1 OP compounds
are generally used for DSP with suicidal intention because
of their well known fatality index.4
In Western countries DSP related mortality is low,
about 0.3%.3 Overall fatality in India, China, and Srilanka is
>10%,4 whereas mortality noted in Pakistani studies
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